Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suprachoroidal Triamcinolone Acetonide for RVO-associated Macular Edema
NCT05038072Completed
- Sponsor
- Damascus University
- Start
- Jul 2019
- Primary completion
- Nov 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of triamcinolone acetonide in macular edema, sponsored by Damascus University. Primary endpoints: Percentage of participants with BCVA gain >= 15 Letters at 3 months and Percentage of participants with IOP >= 20 mm Hg at 3 months. Started Jul 2019; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT05038072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038072.